Status: Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Participants needed: 411
Trial details
Phase: Phase 1Age: 12-85Biological sex: AllType: InterventionalSponsor: Inhibrx Biosciences, IncUpdated: May 22, 2026Locations: 36
Eligibility criteria
Males or females aged ≥12 to less than 85 years for Ewing sarcoma and 18 to less... [+8]
Prior treatment with or exposure to DR5 agonists. [+17]